Kurioka Takaomi, Sano Hajime, Furuki Shogo, Yamashita Taku
Department of Otorhinolaryngology, Head and Neck Surgery, Kitasato University, Kanagawa, Japan.
School of Allied Health Sciences, Kitasato University, Kanagawa, Japan.
PeerJ. 2020 Dec 16;8:e10406. doi: 10.7717/peerj.10406. eCollection 2020.
In idiopathic sudden sensorineural hearing loss (ISSNHL), the relationship between the administration duration of vitamin B12 (vit B12) with adenosine triphosphate (ATP) and their therapeutic effect is not fully understood.
To investigate the therapeutic effect of long-term 16 (≥weeks) administration of vit B12 with ATP on the prognosis of ISSNHL patients and compare it with those of short-term (<8 weeks) and middle-term (≥8 weeks, <16 weeks) administration.
We retrospectively reviewed the medical records of 117 patients with ISSNHL treated between 2015 and 2018.
The overall recovery rate was 32.5%. Initial higher hearing threshold and initial higher grade of hearing loss (HL) were associated with a poor prognosis. However, the administration duration of vit B12 and ATP did not influence the overall hearing improvement. With regard to the time course of hearing recovery, there was no significant difference in hearing recovery among the long-, middle-, and short-term administration groups until 16 weeks after treatment. However, at 16-24 weeks after initial treatment, the short-term administration group exhibited significantly lower hearing recovery than did the long-term administration groups.
The administration duration of vit B12 and ATP did not influence the overall hearing prognosis in ISSNHL, but long-term administration of vit B12 and ATP helped prevent the progression of HL after ISSNHL. Our results suggest that long-term administration of vit B12 and ATP is not necessarily required to treat ISSNHL patients, except for slowly progressing HL in the affected ears.
在特发性突发性感音神经性听力损失（ISSNHL）中，维生素B12（vit B12）与三磷酸腺苷（ATP）的给药持续时间与其治疗效果之间的关系尚未完全明确。
探讨长期（≥16周）给予vit B12联合ATP对ISSNHL患者预后的治疗效果，并与短期（<8周）和中期（≥8周，<16周）给药的效果进行比较。
我们回顾性分析了2015年至2018年间接受治疗的117例ISSNHL患者的病历。
总体恢复率为32.5%。初始听力阈值较高和初始听力损失（HL）分级较高与预后不良相关。然而，vit B12和ATP的给药持续时间并未影响总体听力改善情况。关于听力恢复的时间进程，在治疗后16周内，长期、中期和短期给药组的听力恢复情况无显著差异。然而，在初始治疗后的16 - 24周，短期给药组的听力恢复明显低于长期给药组。
vit B12和ATP的给药持续时间不影响ISSNHL的总体听力预后，但长期给予vit B12和ATP有助于预防ISSNHL后HL的进展。我们的结果表明，除患耳HL进展缓慢外，治疗ISSNHL患者不一定需要长期给予vit B12和ATP。
